Dementia update 2005

Alzheimer Disease and Associated Disorders

Volumn 19, Issue 2, 2005, Pages 100-117

  Morris, John C ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; DONEPEZIL; ESTROGEN; GALANTAMINE; PLACEBO; RIVASTIGMINE;

CLINICAL TRIAL; COGNITIVE DEFECT; CREUTZFELDT JAKOB DISEASE; DEMENTIA; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIET; DISEASE COURSE; DOSE RESPONSE; FRONTOTEMPORAL DEMENTIA; GENETIC PREDISPOSITION; HIPPOCAMPAL SCLEROSIS; HUMAN; INCIDENCE; INFLAMMATION; LEWY BODY; LIFESTYLE; MULTIINFARCT DEMENTIA; NEUROFIBRILLARY TANGLE; NEUROIMAGING; PREVALENCE; PRION DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENILE PLAQUE;

ANIMALS; BRAIN; DEMENTIA; HUMANS; LIFE STYLE; RISK FACTORS;

EID: 23044503240     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wad.0000167923.56275.d8     Document Type: Review

References (209)

1. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population. Arch Neurol. 2003;60:1119-1122.
2. Kukull WA, Higdon R, Bowen JD, et al. Dementia and Alzheimer disease incidence; a prospective cohort study. Arch Neurol. 2002;59:1737-1746.
3. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health. 1994;84:1261-1264.
4. Larson EB, Shadlen MF, Wang L, et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med. 2004;140:501-509.
5. Tschanz JT, Corcoran C, Skoog I, et al. Dementia: the leading predictor of death in a defined elderly population; The Cache County Study. Neurology. 2004;62:1156-1162.
6. Schellenberg GD. Alzheimer disease genes; Presenilin 2 mutation number 9 and still counting [editorial]. Arch Neurol. 2003;60:1521-1522.
7. Graff-Radford NR, Green RC, Go RCP, et al. Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. Arch Neurol. 2002;59:594-600.
8. Green RC, Cupples LA, Go R, et al. Risk of dementia among white and African American relatives of patients with Alzheimer's disease. JAMA. 2002;287:329-336.
9. Bian L, Yang JD, Guo TW, et al. Insulin-degrading enzyme and Alzheimer disease: a genetic association study in the Han Chinese. Neurology. 2004;63:241-245.
10. Li Y, Nowotny P, Holmans P, et al. Association of late-onset Alzheimer's disease with genetic variation in multiple members of the GAPD gene family. Proc Natl Acad Sci USA. 2004;101:15688-15693.
11. Pedersen NL, Gatz M, Berg S, et al. How heritable is Alzheimer's disease late in life? Findings from Swedish twins. Ann Neurol. 2004;55:180-185.
12. Silverman JM, Smith CJ, Marin DB, et al. Familial patterns of risk in very late-onset Alzheimer's disease. Arch Gen Psychiatry. 2003;60:190-197.
13. Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet. 2004;363:1139-1146.
14. Elkins JS, O'Meara ES, Longstreth WT, et al. Stroke risk factors and loss of high cognitive function. Neurology. 2004;63:793-799.
15. Sachdev PS, Brodaty H, Valenzuela MJ, et al. Progression of cognitive impairment in stroke patients. Neurology. 2004;63:1618-1623.
16. Ballard CG, Morris CM, Rao H, et al. APOE ε4 and cognitive decline in older stroke patients with early cognitive impairment. Neurology. 2004;63:1399-1402.
17. Yamada M, Kasagi F, Sasaki H, et al. Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study. J Am Geriatr Soc. 2004;51:410-414.
18. Yaffe K, Blackwell T, Kanaya AM, et al. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology. 2004;63:658-663.
19. Arvanitakis Z, Wilson RS, Bienias JL, et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004;61:661-666.
20. Schnaider Beeri M, Goldbourt U, Silverman JM, et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology. 2004;63:1902-1907.
21. Peila R, Rodriguez BL, White LR, et al. Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology. 2004;63:228-233.
22. Wolf H, Hensel A, Arendt T, et al. Serum lipids and hippocampal volume: the link to Alzheimer's disease? Ann Neurol. 2004;56:745-749.
23. Reitz C, Tang MX, Luchsinger J, et al. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol. 2004;61:705-714.
24. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476-483.
25. Morris MC, Evans DA, Bienias JL, et al. Dietary fat intake and 6-year cognitive change in an older biracial community population. Neurology. 2004;62:1573-1579.
26. Wright CB, Lee H-S, Paik MC, et al. Total homocysteine and cognition in a tri-ethnic cohort; The Northern Manhattan Study. Neurology. 2004;63:254-260.
27. Ott A, Andersen K, Dewey ME, et al. Effect of smoking on global cognitive function in nondemented elderly. Neurology. 2004;62:920-924.
28. Murray MD, Lane KA, Gao S, et al. Preservation of cognitive function with antihypertensive medications. Arch Intern Med. 2002;162:2090-2096.
29. Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet. 2000;356:1627-1631.
30. Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439-1443.
31. Li G, Higdon R, Kukull WA, et al. Statin therapy and risk of dementia in the elderly; a community-based prospective cohort study. Neurology. 2004;63:1624-1628.
32. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
33. Shepherd J, Blauw GJ, Murphy MB. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623-1630.
34. Yaffe K, Kanaya A, Lindquist K, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA. 2004;292:2237-2242.
35. Engelhart MJ, Geerlings MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia. The Rotterdam study. Arch Neurol. 2004;61:668-672.
36. 42 and change presenilin 1 conformation. Nat Med. 2004; 10:1065-1066.
37. In't Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001;345:1515-1521.
38. Zandi PP, Anthony JC, Hayden KM, et al. Reduced incidence of AD with NSAID but not H2 receptor antagonist: The Cache County Study. Neurology. 2002;59:880-886.
39. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289:2819-2826.
40. Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect to Alzheimer's disease in a 1-year, randomized blinded, controlled study. Neurology. 2004;62:66-71.
41. Kalmijn S, Van Boxtel MPJ, Ocke M, et al. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology. 2004;62:275-280.
42. Stampfer MJ, Kang JH, Chen J, et al. Effects of moderate alcohol consumption on cognitive function in women. N Engl J Med. 2005;352:245-253.
43. Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA. 2002;287:3223-3229.
44. Zandi PP, Anthony JC, Khachaturian AS, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements; The Cache County Study. Arch Neurol. 2004;61:82-88.
45. Luchsinger JA, Tang M-X, Shea S, et al. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol. 2003;60:203-208.
46. Miller ER, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37-46.
47. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651-2662.
48. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women. JAMA. 2003;289:2663-2672.
49. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women; Women's Health Initiative Memory Study. JAMA. 2004;291:2959-2968.
50. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women; Women's Health Initiative Memory Study. JAMA. 2004;291:2947-2958.
51. Kang JH, Weuve J, Grodstein F. Postmenopausal hormone therapy and risk of cognitive decline in community-dwelling aging women. Neurology. 2004;63:101-107.
52. Meyer PM, Powell LH, Wilson RS, et al. A population-based longitudinal study of cognitive functioning in the menopausal transition. Neurology. 2003;61:801-806.
53. Wilson RS, Bennett DA, Bienias JL, et al. Cognitive activity and incident AD in a population-based sample of older persons. Neurology. 2002;59:1910-1914.
54. Smyth KA, Fritsch T, Cook TB, et al. Worker functions and traits associated with occupations and the development of AD. Neurology. 2004;63:498-503.
55. Weuve J, Kang JH, Manson JE, et al. Physical activity, including walking, and cognitive function in older women. JAMA. 2004;292:1454-1461.
56. van Gelder BM, Tijhuis MAR, Kalmijn S, et al. Physical activity in relation to cognitive decline in elderly men; the FINE study. Neurology. 2004;63:2316-2321.
57. Barnes LL, Mendes de Leon CF, Wilson RS, et al. Social resources and cognitive decline in a population of older African Americans and whites. Neurology. 2004;63:2322-2326.
58. Holtzman RE, Rebok GW, Saczynski JS, et al. Social network characteristics and cognition in middle-aged and older adults. J Gerontol B Psychol Sci Soc Sci. 2004;59:278-284.
59. Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol. 2004;3:343-353.
60. Berg L, McKeel DW Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55:326-335.
61. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143-1153.
62. AGS Clinical Practice Committee. Guidelines abstracted from the American Academy of Neurology's Dementia Guidelines for early detection, diagnosis, and management of dementia [Special Article]. J Am Geriatr Soc. 2003;51:869-973.
63. Jin Y-P, Gatz M, Johansson B, et al. Sensitivity and specificity of dementia coding in two Swedish disease registries. Neurology. 2004;63:739-741.
64. Ganguli M, Rodriguez E, Mulsant B, et al. Detection and management of cognitive impairment in primary care: the Steel Valley Seniors Survey. J Am Geriatr Soc. 2004;52:1668-1675.
65. Lindeboom R, Schmand B, Holman R, et al. Improved brief assessment of cognition in aging and dementia. Neurology. 2004;63:543-546.
66. Duff Canning SJ, Leach L, Stuss D, et al. Diagnostic utility of abbreviated fluency measures in Alzheimer disease and vascular dementia. Neurology. 2004;62:556-562.
67. Godbolt AK, Cipolotti L, Watt H, et al. The natural history of Alzheimer disease: a longitudinal presymptomatic and symptomatic study of a familial cohort. Arch Neurol. 2004;61:1743-1748.
68. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4 ed. Washington, DC: American Psychiatric Association.
69. Jorm AF. The value of informant reports for assessment and prediction of dementia [editorial]. J Am Geriatr Soc. 2003;51:881-882.
70. Cacchione PZ, Powlishta KK, Grant EA, et al. Accuracy of collateral source reports in very mild to mild dementia of the Alzheimer type. J Am Geriatr Soc. 2003;51:819-823.
71. Tierney MC, Herrmann N, Geslani DM, et al. Contribution of informant and patient ratings to the accuracy of the Mini-Mental State Examination in predicting probable Alzheimer's disease. J Am Geriatr Soc. 2003;51:813-818.
72. Carr DB, Gray S, Baty J, et al. The value of informant vs. individual's complaints of memory impairment in early dementia. Neurology. 2000;55:1724-1726.
73. Edwards ER, Lingquist K, Yaffe K. Clinical profile and course of cognitively normal patients evaluated in memory disorders clinics. Neurology. 2004;62:1639-1642.
74. Ott BR, Heindel WC, Papandonatos GD. A survey of voter participation by cognitively impaired elderly patients. Neurology. 2003;60:1546-1548.
75. Duchek JM, Carr DB, Hunt L, et al. Longitudinal driving performance in early stage dementia of the Alzheimer type. J Am Geriatr Soc. 2003;51:1342-1347.
76. Powlishta KK, Storandt M, Mandernach TA, et al. Absence of effect of depression on cognitive performance in early-stage Alzheimer disease. Arch Neurol. 2004;61:1265-1268.
77. Wilson RS, Schneider JA, Bienias JL, et al. Depressive symptoms, clinical AD, and cortical plaques and tangles in older persons. Neurology. 2003;61:1102-1107.
78. Assal F, Alarcon M, Solomon EC, et al. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Arch Neurol. 2004;61:1249-1253.
79. Folstein MF, Folstein SE, McHugh PR. Mini-mental State: a practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res. 1975;12:189-198.
80. Adak S, Illouz K, Gorman W, et al. Predicting the rate of cognitive decline in aging and early Alzheimer disease. Neurology. 2004;63:108-114.
81. Storandt M, Grant EA, Miller JP, et al. Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology. 2002;59:1034-1041.
82. Scarmeas N, Hadjigeorgiou GM, Papadimitriou A, et al. Motor signs during the course of Alzheimer disease. Neurology. 2004;63:975-982.
83. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154-1166.
84. Santaguida PS, Raina P, Booker L, et al. Pharmacological treatment of dementia. Summary, Evidence Report/Techology Assessment No. 97. U.S. Department of Health and Human Services Public Health Service AHRQ Publication No. 04-E018-1. 2004. Rockville, MD: Agency for Healthcare Research and Quality, McMaster University Evidence-based Practice Center under Contract No. 290-02-0020.
85. Raskind MA, Peskind ER, Truyen L, et al. The cognitive benefits of galantamine are sustained for at least 36 months; a long-term extension trial. Arch Neurol. 2004;61:252-256.
86. Seltzer B, Zolnouni P, Nunez M, et al. Efficacy of donepezil in early-stage Alzheimer disease. Arch Neurol. 2004;61:1852-1856.
87. Feldman H, Gauthier S, Hecker J, et al. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology. 2004;63:644-650.
88. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomized double-blind trial. Lancet. 2004;363:2105-2115.
89. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med. 1997;336:1216-1222.
90. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil; a randomized controlled trial. JAMA. 2004;291:317-324.
91. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents; a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005;62:19-28.
92. Lee PE, Gill SS, Freedman M, et al. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ. 2004;329:75.
93. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia; a review of the evidence. JAMA. 2005;292:596-608.
94. Schneider LS, Tariot PN, Lyketsos CG, et al. National Institute of Mental Health Clinical Antipsychotic trials of intervention effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry. 2001;9:346-360.
95. Frank RA, Galasko D, Hampel H, et al. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging. 2003;24:521-536.
96. Clark CM, Xie S, Chittams J, et al. CSF tau and β-amyloid: How well do these biomarkers reflect autopsy confirmed dementia diagnoses? Arch Neurol. 2003;60:1696-1702.
97. Sunderland T, Linker G, Mirza N, et al. Decreased β-amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003;289:2094-2103.
98. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx. 2004;1:213-225.
99. Schoonenboom NSM, Pijnenburg VAL, Mulder C, et al. Amyloid B(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology. 2004;62:1580-1584.
100. 2-isoprostanes in Alzheimer's disease. J Alzheimers Dis. 2004;6:93-97.
101. Han X, Pagan AM, Cheng H, et al. Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann Neurol. 2003;54:115-119.
102. Phiel CJ, Wilson CA, Lee VMY, et al. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature. 2003;423:435-439.
103. Hye A, Kerr F, Archer N, et al. Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci Lett. 2005;373:1-4.
104. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82:239-259.
105. Ezekiel F, Chao L, Kornak J, et al. Comparisons between global and focal brain atrophy rates in normal aging and Alzheimer disease; boundary shift integral versus tracing of the entorhinal cortex and hippocampus. Alzheimer Dis Assoc Disord. 2004;18:196-201.
106. Rusinek H, Endo Y, DeSanti S, et al. Atrophy rate in medial temporal lobe during progression of Alzheimer disease. Neurology. 2004;63:2354-2359.
107. Kantarci K, Jack CR. Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease. NeuroRx. 2004;1:196-205.
108. Rodrigue KM, Raz N. Shrinkage of the entorhinal cortex over five years predicts memory performance in healthy adults. J Neurosci. 2004;24:956-963.
109. Du AT, Schuff N, Kramer JH, et al. Higher atrophy rate of entorhinal cortex than hippocampus in AD. Neurology. 2004;62:422-427.
110. Miller MI, Hosakari M, Barker AR, et al. Labeled cortical distance maps quantifying cortical change distinguish dementia of the Alzheimer and healthy aging. Proc Natl Acad Sci USA. 2003;100:15172-15177.
111. 1H MR spectroscopy in common dementias. Neurology. 2004;63:1393-1398.
112. Silverman DHS, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001;286:2120-2127.
113. Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:24-35.
114. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-319.
115. Okamura N, Suemoto T, Shimadzu H, et al. Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J Neurosci. 2004;24:2535-2541.
116. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet. 2004;3:519-527.
117. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999;45:358-368.
118. Guillozet AL, Weintraub S, Mash DC, et al. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol. 2003;60:729-736.
119. Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62:1087-1095.
120. Tiraboschi P, Hansen LA, Thal LJ, et al. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology. 2004;62:1984-1989.
121. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351-357.
122. Price JL, Ko AI, Wade MJ, et al. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol. 2001;58:1395-1402.
123. Goldman WP, Price JL, Storandt M, et al. Absence of cognitive impairment or decline in preclinical Alzheimer's disease. Neurology. 2001;56:361-367.
124. Bunce D, Fratiglioni L, Small BJ, et al. APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging. Neurology. 2004;63:816-821.
125. Polvikoski T, Sulkava R, Myllykangas L, et al. Prevalence of Alzheimer's disease in very elderly people; a prospective neuropathological study. Neurology. 2001;56:1690-1696.
126. Saxton J, Lopez OL, Ratcliff G, et al. Preclinical Alzheimer disease; neuropsychological test performance 1.5 to 8 years prior to onset. Neurology. 2004;63:2341-2347.
127. Kawas CH, Corrada MM, Brookmeyer R, et al. Visual memory predicts Alzheimer's disease more than a decade before diagnosis. Neurology. 2003;60:1089-1093.
128. Nestor PJ, Scheltens P, Hodges JR. Advances in the early detection of Alzheimer's disease. Nat Med. 2004;10:S34-S41.
129. Oddo S, Billings L, Kesslak JP, et al. AB immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43:321-332.
130. Yamaguchi H, Sugihara S, Ogawa A, et al. Alzheimer β amyloid deposition enhanced by ApoE ε4 gene precedes neurofibrillary pathology in the frontal association cortex of nondemented senior subjects. J Neuropathol Exp Neurol. 2001;60:731-739.
131. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486-489.
132. Lacor PN, Buniel MC, Chang L, et al. Synaptic targeting by Alzheimer's-related amyloid B oligomers. J Neurosci. 2004;24:10191-10200.
133. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid B protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2004;416:535-539.
134. Tsai J, Grutzendler J, Duff K, et al. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci. 2004;7:1181-1183.
135. Nitsch RM. Immunotherapy of Alzheimer disease. Alzheimer Dis Assoc Disord. 2004;18:185-189.
136. Lombardo JA, Stern EA, McLellan ME, et al. Amyloid-β antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci. 2003;23:10879-10883.
137. Brendza RP, Bacskai BJ, Cirrito JR, et al. Anti-Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest. 2005:115.
138. Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic AB42 (AN1792) in patients with AD. Neurology. 2005;64:94-101.
139. Nicoll JAR, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med. 2003;9:448-452.
140. 42 immunization. Neurology. 2003;61:46-54.
141. Ferrer I, Rovira MB, Guerra MLS, et al. Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer's disease. Brain Pathol. 2004;14:11-20.
142. Masliah E, Hansen L, Adame A, et al. AB vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 2005;64:129-131.
143. Bennett DA, Holtzman DM. Immunization therapy for Alzheimer disease? Neurology. 2005;64:10-12.
144. Wilcock DM, Rojiani A, Rosenthal A, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci. 2004;24:6144-6151.
145. Qu B, Rosenberg RN, Li L, et al. Gene vaccination to bias the immune response to amyloid-β peptide as therapy for Alzheimer disease. Arch Neurol. 2004;61:1859-1864.
146. Selkoe DJ. Alzheimer Disease: Mechanistic understanding predicts novel therapies. Ann Intern Med. 2004;140:627-638.
147. Ritchie CW, Bush AI, MacKinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease. A pilot phase 2 clinical trial. Arch Neurol. 2003;60:1685-1691.
148. Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of Aβ oligomers and fibrils, binds plaques and reduces amyloid in vivo. J Biol Chem. 2004.
149. Zhang B, Maiti A, Shively S, et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA. 2005;102:227-231.
150. Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1133-1142.
151. Levy R. Aging-associated cognitive decline. Int Psychogeriatr. 1994;6:63-68.
152. Graham JE, Rockwood K, Beattie LB, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997;349:1793-1796.
153. Fisk JD, Merry HR, Rockwood K. Variations in case definition affect prevalence but not outcomes of mild cognitive impairment. Neurology. 2003;61:1179-1184.
154. Ganguli M, Dodge HH, Shen C, et al. Mild cognitive impairment, amnestic type; an epidemiologic study. Neurology. 2004;63:115-121.
155. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment-beyond controversies, towards a consensus: Report of the International Working Group on mild cognitive impairment. J Intern Med. 2004;256:240-246.
156. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183-194.
157. Griffith HR, Belue K, Sicola A, et al. Impaired financial abilities in mild cognitive impairment. Neurology. 2003;60:449-457.
158. Grundman M, Petersen RC, Ferris SH, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004;61:59-66.
159. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer's disease. Arch Neurol. 2001;58:397-405.
160. Feldman H, Scheltens P, Scarpini E, et al. Behavioral symptoms in mild cognitive impairment. Neurology. 2004;62:1199-1201.
161. Modrego PJ, Ferrandez J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Arch Neurol. 2004;61:1290-1293.
162. Dik MG, Jonker C, Bouter LM, et al. APOE-ε4 is associated with memory decline in cognitively impaired elderly. Neurology. 2000;54:1492-1497.
163. Farlow MR, He Y, Tekin S, et al. Impact of APOE in mild cognitive impairment. Neurology. 2004;63:1898-1901.
164. Jack CR, Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004;62:591-600.
165. Korf ESC, Wahlund L-O, Visser PJ, et al. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology. 2004;63:94-100.
166. Mosconi L, Perani D, Sorbi S, et al. MCI conversion to dementia and the APOE genotype; a prediction study with FDG-PET. Neurology. 2004;63:2332-2340.
167. Kordower JH, Chu Y, Stebbins GT, et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol. 2001;49:202-213.
168. Pratico D, Clark CM, Liun F, et al. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol. 2002;59:972-976.
169. Yang Y, Mufson EJ, Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurol Sci. 2003;23:2557.
170. DeKosky ST, Ikonomovic MD, Styren SD, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002;51:145-155.
171. Salloway S, Ferris S, Kluger A, et al. Efficacy of donepezil in mild cognitive impairment; A randomized placebo-controlled trial. Neurology. 2004;63:651-657.
172. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005:352, www.nejm.org (10.1056/NEJMoa050151).
173. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology. 2000;54:S4-S9.
174. Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002;16:203-212.
175. Petrovitch H, Ross GW, Steinhorn SC, et al. AD lesions and infarcts in demented and non-demented Japanese-American men. Ann Neurol. 2005;57:98-103.
176. Langa KM, Foster NL, Larson EB. Mixed dementia; emerging concepts and therapeutic implications. JAMA. 2004;292:2901-2908.
177. White L, Petrovitch H, Hardman J, et al. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia aging study participants. Ann N Y Acad Sci. 2002;977:9-23.
178. Sachdev PS, Brodaty H, Valenzuela MJ, et al. The neuropsychological profile of vascular cognitive impairment in stroke and T1A patients. Neurology. 2004;62:912-919.
179. Schneider JA, Wilson RS, Bienias JL, et al. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology. 2004;62:1148-1155.
180. Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359:1283-1290.
181. Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003;61:479-486.
182. Malouf R, Birks J. Donepezil for vascular cognitive impairment (Cochrane Review). The Cochrane Library 2004.
183. Ohtake H, Limprasert P, Fan Y, et al. B-Synuclein gene alterations in dementia with Lewy bodies. Neurology. 2004;63:805-811.
184. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113-1124.
185. Ballard CG. Definition and diagnosis of dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2004;17:15-24.
186. Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology. 2003;60:1586-1590.
187. Villareal DT, Grant E, Miller JP, et al. Clinical outcomes of possible versus probable Alzheimer's disease. Neurology. 2003;61:661-667.
188. Boeve BF, Silber MH, Parisi JE, et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology. 2004;61:40-45.
189. Ferman TJ, Smith GE, Boeve BF, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology. 2004;62:181-187.
190. Louis ED, Tang MX, Mayeux R. Parkinsonian signs in older people in a community-based study. Arch Neurol. 2004;61:1273-1276.
191. Aarsland D, Andersen K, Larsen JP, et al. The rate of cognitive decline in Parkinson disease. Arch Neurol. 2004;61:1906-1911.
192. Bonelli SB, Ransmayr G, Steffelbauer M, et al. L-Dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology. 2004;63:376-378.
193. Mosimann UP, Mather G, Wesnes KA, et al. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology. 2004;63:2091-2096.
194. O'Brien JT, Colloby S, Fenwick J, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol. 2004;61:919-925.
195. Knopman DS, Petersen RC, Edland SD, et al. The incidence of frontotemporal lobar degeneration in Rochester, Minnesota, 1990 through 1994. Neurology. 2004;62:506-508.
196. Knopman DS, Boeve BF, Parisi JE, et al. Antemortem diagnosis of frontotemporal lobar degeneration. Ann Neurol. 2005;57:480-488.
197. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546-1554.
198. Hodges JR, Davies RR, Xuereb JH, et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol. 2004;56:399-406.
199. Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002;59:1077-1079.
200. Bigio EH, Johnson NA, Rademaker AW, et al. Neuronal ubiquitinated intranuclear inclusions in familial and non-familial frontotemporal dementia of the motor neuron disease type associated with amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2004;63:801-811.
201. Cairns NJ, Grossman M, Arnold SE, et al. Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology. 2004;63:1376-1384.
202. DeKosky ST, Ikonomovic MD. NIFID: a new molecular pathology with a frontotemporal dementia phenotype (Editorial). Neurology. 2004;63:1348-1349.
203. Blass DM, Hatanpaa KJ, Brandt J, et al. Dementia in hippocampal sclerosis resembles frontotemporal dementia more than Alzheimer disease. Neurology. 2004;63:492-497.
204. Hatanpaa KJ, Blass DM, Pletnikova O, et al. Most cases of dementia with hippocampal sclerosis may represent frontotemporal dementia. Neurology. 2004;63:538-542.
205. Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol. 2000;1999:224-233.
206. Castellani RJ, Colucci M, Xie Z, et al. Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease. Neurology. 2004;63:436-442.
207. Shiga Y, Miyazawa K, Sato S, et al. Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease. Neurology. 2004;63:443-449.
208. Meissner B, Kohler K, Kortner K, et al. Sporadic Creutzfeldt-Jakob disease; magnetic resonance imaging and clinical findings. Neurology. 2004;63:450-456.
209. Haik S, Brandel JP, Salomon D, et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology. 2004;63:2413-2415.